Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation
Molex, parent company of Phillips Medisize, has announced an agreement to acquire Vectura Group from Philip Morris International (NYSE: PM). This acquisition aims to expand Phillips Medisize's drug delivery capabilities in inhalation. Vectura, based in Chippenham, UK, is a leader in inhalation drug device design and formulation.
The combination of Phillips Medisize and Vectura will enhance their ability to deliver a broader portfolio of inhalation combination drug devices and solutions to pharmaceutical customers. Vectura brings expertise in formulation and device development for various inhalation products, including dry powder inhalers, pressurized metered dose inhalers, and nasal and nebulizer products.
The acquisition is expected to close by the end of 2024, subject to regulatory approvals and other customary closing conditions.
Molex, società madre di Phillips Medisize, ha annunciato un accordo per acquisire Vectura Group da Philip Morris International (NYSE: PM). Questa acquisizione ha l'obiettivo di espandere le capacità di somministrazione di farmaci per inalazione di Phillips Medisize. Vectura, con sede a Chippenham, Regno Unito, è un leader nella progettazione e formulazione di dispositivi per farmaci inalatori.
La combinazione di Phillips Medisize e Vectura migliorerà la loro capacità di offrire un portafoglio più ampio di dispositivi e soluzioni combinate per farmaci inalatori ai clienti farmaceutici. Vectura porta con sé competenze nella formulazione e nello sviluppo di dispositivi per vari prodotti per inalazione, tra cui inalatori a polvere secca, inalatori a dose metered pressurizzati e prodotti nasali e nebulizzatori.
Si prevede che l'acquisizione si concluda entro la fine del 2024, soggetta ad approvazioni normative e altre condizioni di chiusura abituali.
Molex, empresa matriz de Phillips Medisize, ha anunciado un acuerdo para adquirir Vectura Group de Philip Morris International (NYSE: PM). Esta adquisición tiene como objetivo expandir las capacidades de entrega de medicamentos por inhalación de Phillips Medisize. Vectura, con sede en Chippenham, Reino Unido, es un líder en diseño y formulación de dispositivos para medicamentos inhalados.
La combinación de Phillips Medisize y Vectura potenciará su capacidad para ofrecer una cartera más amplia de dispositivos y soluciones combinadas para medicamentos inhalados a sus clientes farmacéuticos. Vectura aporta experiencia en formulación y desarrollo de dispositivos para varios productos de inhalación, incluidos inhaladores de polvo seco, inhaladores de dosis medida presurizados y productos nasales y nebulizadores.
Se espera que la adquisición se cierre a finales de 2024, sujeta a aprobaciones regulatorias y otras condiciones de cierre habituales.
Molex는 Phillips Medisize의 모회사로서 Philip Morris International(NYSE: PM)으로부터 Vectura Group을 인수하기 위한 계약을 발표했습니다. 이번 인수는 Phillips Medisize의 흡입에 대한 약물 전달 능력을 확장하는 것을 목표로 하고 있습니다. Vectura는 영국 치펜햄에 본사를 두고 있으며, 흡입 약물 장치 설계 및 제형 분야에서 선두주자입니다.
Phillips Medisize와 Vectura의 결합은 제약 고객에게 흡입 조합 약물 장치 및 솔루션의 더 다양한 포트폴리오를 제공할 수 있는 능력을 향상시킬 것입니다. Vectura는 여러 흡입 제품을 위한 제형 및 장치 개발에 대한 전문성을 제공하며, 여기에는 건조 분말 흡입기, 압축 미터 doses 흡입기 및 비강 및 네뷸라이저 제품이 포함됩니다.
이번 인수는 2024년 말까지 완료될 것으로 예상되며, 규제 승인 및 기타 전통적인 종료 조건에 따라 달라질 수 있습니다.
Molex, la société mère de Phillips Medisize, a annoncé un accord pour acquérir Vectura Group de Philip Morris International (NYSE: PM). Cette acquisition vise à élargir les capacités de livraison de médicaments de Phillips Medisize par inhalation. Vectura, basé à Chippenham, au Royaume-Uni, est un leader dans la conception et la formulation de dispositifs de médicaments inhalés.
La combinaison de Phillips Medisize et Vectura renforcera leur capacité à fournir un portefeuille plus large de dispositifs et solutions combinés pour médicaments inhalés aux clients pharmaceutiques. Vectura apporte son expertise dans la formulation et le développement de dispositifs pour divers produits d'inhalation, y compris les inhalateurs à poudre sèche, les inhalateurs à dose mesurée sous pression, ainsi que les produits nasaux et les nébuliseurs.
L'acquisition devrait être finalisée d'ici la fin de 2024, sous réserve des approbations réglementaires et d'autres conditions de clôture habituelles.
Molex, das Mutterunternehmen von Phillips Medisize, hat eine Vereinbarung zur Übernahme von Vectura Group von Philip Morris International (NYSE: PM) angekündigt. Mit dieser Übernahme soll die Fähigkeit von Phillips Medisize zur Abgabe von Arzneimitteln durch Inhalation erweitert werden. Vectura mit Sitz in Chippenham, Großbritannien, ist führend im Design und in der Formulierung von inhalativen Arzneimitteln.
Die Kombination von Phillips Medisize und Vectura wird ihre Fähigkeit verbessern, ein breiteres Portfolio von Kombinationsarzneimitteln und inhalativen Geräte-Lösungen für pharmazeutische Kunden anzubieten. Vectura bringt Expertise in der Formulierung und Gerätentwicklung für verschiedene inhalative Produkte mit, darunter Trockenpulverinhalatoren, druckgesteuerte Dosierinhalatoren sowie Produkte für die Nase und Vernebelungsgeräte.
Die Übernahme wird voraussichtlich bis Ende 2024 abgeschlossen sein, vorbehaltlich der regulatorischen Genehmigungen und anderer üblichen Abschlussbedingungen.
- Expansion of Phillips Medisize's drug delivery capabilities in inhalation
- Addition of Vectura's expertise in inhalation drug device design and formulation
- Broader portfolio of inhalation combination drug devices and solutions for pharmaceutical customers
- Potential for increased market share in the inhalation therapy sector
- Access to Vectura's pharmaceutical analysis, process development, and regulatory services
- Regulatory approvals required for acquisition completion
- Potential integration challenges between Phillips Medisize and Vectura
- Acquisition costs and potential short-term financial impact on Molex
The acquisition of Vectura by Molex, parent company of Phillips Medisize, is a strategic move to expand its drug delivery capabilities, particularly in inhalation devices. This deal could significantly enhance Molex's market position in the pharmaceutical industry. While financial details aren't disclosed, the acquisition is likely to boost Molex's revenue in the long term, given Vectura's expertise in inhalation drug delivery systems. The deal also diversifies Molex's portfolio, potentially reducing risk and opening new growth opportunities. However, investors should note that the closing is not expected until the end of 2024, subject to regulatory approvals, which introduces some uncertainty.
This acquisition marks a significant development in the inhalation drug delivery sector. Vectura's expertise in formulation and device development for various inhalation products, including DPIs, pMDIs and nasal devices, complements Phillips Medisize's manufacturing capabilities. This synergy could accelerate innovation in treatments for respiratory diseases like asthma and COPD. The combined entity will likely have enhanced capabilities to develop complex drug-device combinations, potentially leading to more effective therapies. This move also reflects the growing importance of specialized drug delivery systems in the pharmaceutical industry, particularly for biologics and complex molecules that require precise delivery mechanisms.
The inhalation drug delivery market is projected for substantial growth, driven by the increasing prevalence of respiratory diseases and the need for more efficient drug delivery systems. This acquisition positions Molex and Phillips Medisize to capitalize on this trend. By integrating Vectura's specialized knowledge with their existing capabilities, they can offer end-to-end solutions from formulation to manufacturing, potentially attracting more pharmaceutical clients. The move also diversifies their customer base and could lead to increased market share. However, the long timeline to closing (
- Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize
- Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities
- Vectura employees to join a large global company, dedicated to improving patients’ lives through innovative products and world class quality and manufacturing capabilities
“Combining the strengths of Phillips Medisize and Vectura will enhance our ability to deliver a broader portfolio of inhalation combination drug devices and solutions to our pharmaceutical customers and support our mission to help people live healthier, more productive lives,” said Paul Chaffin, President of Phillips Medisize. “With our global reach, manufacturing scale, and engineering expertise, Phillips Medisize is uniquely positioned to help Vectura in developing innovative new products for their customers, ultimately benefiting people who suffer with chronic and acute diseases such as asthma and COPD.”
Vectura brings to Phillips Medisize its unique inhalation expertise that includes formulation and device development for dry powder inhalers (DPI), pressurized metered dose inhalers (pMDI), nasal and nebulizer products for small molecules, biologics, complex combinations and generic products. The company also offers pharmaceutical analysis, process development, technical transfer, clinical trial supplies and regulatory services.
Phillips Medisize is a global company that designs, engineers and manufactures products for the pharmaceutical and broader healthcare industry. The company’s 6,000+ employees collaborate with customers at 29 sites located throughout
“The acquisition of Vectura is the latest step in building an industry-leading capability in medical. It also demonstrates Molex’s commitment to acquiring opportunities to better serve market needs across our portfolio,” said Joe Nelligan, CEO of Molex, which acquired Phillips Medisize in 2016 to build a scale healthcare business. “We are excited by the significant growth potential that comes with a wider range of formulation, device design, combination product development and manufacturing services to support the increasing need for inhalation therapies. We look forward to welcoming the Vectura team, who brings a celebrated reputation of inhalation expertise and experience.”
The acquisition is expected to close by the end of 2024, subject to regulatory approvals and other customary closing conditions.
About Phillips Medisize
Phillips Medisize, a Molex company, collaborates with leading pharmaceutical, medical technology and in vitro diagnostic companies to design, engineer and manufacture life-saving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit www.phillipsmedisize.com.
About Molex
Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 40 countries, Molex enables transformative technology innovation in the automotive, data center, industrial automation, healthcare, 5G, cloud and consumer device industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit www.molex.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916819174/en/
Jeff Speer, Merryman Communications
+1-916-397-5595
jeff@merrymancommunications.com
Source: Molex
FAQ
What company is Molex acquiring in the inhalation drug delivery space?
How will the acquisition of Vectura benefit Phillips Medisize's customers?
What specific expertise does Vectura bring to Phillips Medisize?
When is the acquisition of Vectura by Molex expected to close?
How does this acquisition align with Molex's business strategy?
